Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,246.00
Bid: 1,242.00
Ask: 1,246.00
Change: 20.00 (1.63%)
Spread: 4.00 (0.322%)
Open: 1,220.00
High: 1,246.00
Low: 1,220.00
Prev. Close: 1,226.00
VCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Victrex plc - Q3 Interim Management Statement

6 Jul 2023 07:00

RNS Number : 1185F
Victrex PLC
06 July 2023
 
 

 

6 July 2023

Victrex plc - Q3 Interim Management Statement

Volumes lower on macro-economic weakness; further price improvement

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and bring environmental and societal benefit in multiple end-markets. Today's Interim Management Statement for Q3 covers the period 1 April 2023 to 30 June 2023.

Performance summary - Q3 in line with guidance

As previously communicated in our trading update of 14 June 2023 and at our interim results, compared to a record prior year period, the Group is seeing ongoing macro-economic weakness and destocking across several end markets.

The Group continues to be well positioned for a macro-economic recovery.

Q3 saw further improvement in average selling prices (ASP), taking year-to-date ASP to £85/kg, supported by price increases, sales mix and currency. We now anticipate that full year ASP will be above £84/kg. This in turn, together with easing energy costs, means we are seeing gross margin improvement during the second half, compared to the prior year, but it will be slightly held back by lower asset utilisation.

Further progress in mega-programmes; E-mobility exceeding expectations

Further progress was seen in commercial milestones within our 'mega-programme' growth pipeline, particularly in E-mobility and Trauma. We now anticipate annual revenues in our E-mobility mega-programme will exceed our original expectations, reaching £5m in FY 2023. In Trauma, we are making good progress with our PEEK composite Trauma plates, serving growing demand in the US and Asia. Run-rates are building towards £1m revenue and further growth in both E-mobility and Trauma is expected in FY 2024.

Q3 performance:

· Q3 Group revenue down 23% to £72.2m (Q3 2022: £93.4m)

· Q3 Group volume down 38% to 818 tonnes (Q3 2022: 1,323 tonnes)

· Year to date Group revenue of £234.4m is 8% down on the prior year (2022 YTD: £253.5m), with YTD Group volume of 2,759 tonnes being 23% down on the prior year (2022 YTD: 3,586 tonnes)

· Q3 weakness driven by Electronics, Energy & Industrial and Value Added Resellers

· Aerospace seeing good growth; Automotive stable YTD

· Medical performing strongly; YTD revenue continues to track up double-digit

 

 

 

Financial position

Victrex retains a highly cash generative business model, which supports growth investment and shareholder returns. Capital expenditure this year is focused on our China manufacturing investments, with our new PEEK polymer facility having delivered first polymer ahead of commercial start up by the end of 2023. Total cash on 30 June 2023 was £27m, which includes £3.5m cash ringfenced in China investments. Capital expenditure will start to step down from FY 2024, supporting improving cashflows.

 

Outlook unchanged

Jakob Sigurdsson, Chief Executive of Victrex, said: "In line with our recent trading update, we continue to be impacted by ongoing macro-economic weakness and destocking in several end markets. Compared to a record prior year period, lower Q3 volumes were driven by Electronics, Energy & Industrial and Value Added Resellers. Aerospace and Medical continue to perform strongly, whilst Automotive is stable year-to-date.

 

"Overall, our Outlook is unchanged from what we recently communicated, with full-year adjusted (pre-exceptional) PBT expected to be in the range of £80m-£85m. As we move into the final quarter, strong average selling prices, mix, energy costs and cost discipline remain supportive, and we continue to be well-placed for when the macro-economic environment improves.

 

"On a medium to long term basis, we have a strong and diverse core business, growing commercialisation in our mega-programmes, capital investment which is set to reduce and support improving cash flows, and strong ESG credentials."

 

Victrex will report its Preliminary Results for 2023 on Tuesday 4 December 2023.

 

Analyst & investor call:

A call for analysts & investors will be held today, Thursday 6 July, at 08.30am UK time. To register for the call please follow this link:

https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=3197336&linkSecurityString=82f3181b0

 

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTBCGDRISGDGXU
Date   Source Headline
28th Mar 20249:56 amRNSTotal Voting Rights
15th Mar 20248:30 amRNSDirectorate Change
6th Mar 20242:06 pmRNSDirector/PDMR Shareholding
29th Feb 20249:36 amRNSTotal Voting Rights
21st Feb 20248:00 amRNSBlock listing Interim Review
9th Feb 202412:16 pmRNSResult of AGM
9th Feb 20247:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202412:26 pmRNSTotal Voting Rights
25th Jan 202410:57 amRNSHolding(s) in Company
9th Jan 202412:13 pmRNSAnnual Report & Accounts
29th Dec 20239:00 amRNSTotal Voting Rights
12th Dec 202310:21 amRNSDirector/PDMR Shareholding
5th Dec 20232:42 pmRNSDirector/PDMR Shareholding
5th Dec 20232:33 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSVictrex plc - Preliminary Results 2023
1st Dec 202310:41 amRNSBlock listing Interim Review
30th Nov 202311:10 amRNSTotal Voting Rights
3rd Nov 20231:31 pmRNSHolding(s) in Company
31st Oct 20239:36 amRNSTotal Voting Rights
19th Sep 20231:59 pmRNSDirector/PDMR Shareholding
8th Sep 20239:32 amRNSHolding(s) in Company
31st Aug 20239:30 amRNSTotal Voting Rights
23rd Aug 202310:52 amRNSHolding(s) in Company
17th Aug 20231:27 pmRNSDirector/PDMR Shareholding
31st Jul 20239:39 amRNSTotal Voting Rights
18th Jul 202311:51 amRNSDirector/PDMR Shareholding
13th Jul 20232:00 pmRNSAdditional Listing
6th Jul 20237:00 amRNSVictrex plc - Q3 Interim Management Statement
3rd Jul 20234:03 pmRNSHolding(s) in Company
30th Jun 20239:37 amRNSTotal Voting Rights
27th Jun 202310:08 amRNSDirector/PDMR Shareholding
19th Jun 20232:27 pmRNSDirector/PDMR Shareholding
14th Jun 20237:00 amRNSTrading Statement
1st Jun 202312:08 pmRNSBlock listing Interim Review
31st May 20239:52 amRNSTotal Voting Rights
17th May 202310:55 amRNSDirector/PDMR Shareholding
16th May 202310:03 amRNSDirector/PDMR Shareholding
12th May 202310:37 amRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding
10th May 20231:34 pmRNSDirector/PDMR Shareholding
9th May 20237:00 amRNSVictrex plc - Interim Results 2023
28th Apr 20239:33 amRNSTotal Voting Rights
18th Apr 20232:00 pmRNSHolding(s) in Company
18th Apr 202310:50 amRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSDirectorate Change
31st Mar 202310:52 amRNSTotal Voting Rights
20th Mar 20233:07 pmRNSHolding(s) in Company
20th Mar 202310:15 amRNSDirector/PDMR Shareholding
13th Mar 202310:14 amRNSAdditional Listing
28th Feb 20239:35 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.